Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Celebrate National Volunteer Month with AARP Foundation. Learn ...